Cure My Disease

Don't miss your cure!

 Log in / Sign up

Scientists dig into the DNA of drug-resistant lung cancers to find hidden clues

NCT ID NCT07122882

ENROLLING_BY_INVITATION Knowledge-focused Sponsor: Chang Gung Memorial Hospital Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study enrolls 40 people with non-small cell lung cancer whose tumors have stopped responding to targeted therapy (tyrosine kinase inhibitors). Researchers will analyze the tumors' full genetic code and RNA to find new resistance mechanisms. The goal is to better understand why these cancers become resistant, not to test a new treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to

If successful, this could reveal new genetic reasons why lung cancers become resistant to targeted therapies, pointing toward future treatment strategies.

What could go wrong

This is a small, early-stage observational study (40 people) that does not test a new treatment. It may not find clear or actionable resistance mechanisms.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ROS1 FUSION POSITIVE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

central nervous system cancer non-small cell lung carcinoma NTRK fusion positive cancer RET fusion positive cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ALK FUSION-POSITIVE SOLID OR CNS TUMORS BRAF V600 MUTATION EGFR MUTATION ERBB2 MUTATION-RELATED TUMORS KRAS G12C MUTATION MET EXON 14 SKIPPING MUTATION NRG1 FUSION NTRK1 FUSION POSITIVE NTRK2 FUSION POSITIVE NTRK3 FUSION POSITIVE ONCOGENE-ADDICTED NON SMALL CELL LUNG CANCER RET FUSION POSITIVE ROS1 FUSION POSITIVE

Contacts and locations

Locations

  • Chang Gung Memorial Hospital Linkou Branch

    Taoyuan, 333, Taiwan